Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.

Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK.

Lung Cancer. 2016 Aug;98:76-8. doi: 10.1016/j.lungcan.2016.05.014. Epub 2016 May 25.

PMID:
27393510
2.

Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?

Clarke JM, Wang X, Ready NE.

Transl Lung Cancer Res. 2015 Dec;4(6):804-8. doi: 10.3978/j.issn.2218-6751.2015.05.03.

3.

Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients.

Wang Y, Liu H, Ready NE, Su L, Wei Y, Christiani DC, Wei Q.

Int J Cancer. 2016 Jun 1;138(11):2592-601. doi: 10.1002/ijc.29991. Epub 2016 Jan 30.

PMID:
26757251
4.

Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study.

Kelsey CR, Christensen JD, Chino JP, Adamson J, Ready NE, Perez BA.

Pract Radiat Oncol. 2016 Mar-Apr;6(2):96-104. doi: 10.1016/j.prro.2015.10.009. Epub 2015 Oct 23.

PMID:
26723555
5.

Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).

Salama JK, Gu L, Wang X, Pang HH, Bogart JA, Crawford J, Schild SE, Vokes EE, Ready NE.

J Thorac Oncol. 2016 Mar;11(3):361-9. doi: 10.1016/j.jtho.2015.11.001. Epub 2015 Dec 24.

PMID:
26723241
6.

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators.

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.

PMID:
26637834
7.

Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.

Kelsey CR, Das S, Gu L, Dunphy FR 3rd, Ready NE, Marks LB.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):997-1004. doi: 10.1016/j.ijrobp.2015.09.007. Epub 2015 Sep 15.

PMID:
26581138
8.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR.

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

PMID:
26412456
9.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE.

J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.

10.

Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

Pepek JM, Marks LB, Berry MF, Ready NE, Gee NG, Coleman RE, D'Amico TA, Crawford J, Kelsey CR.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):79-84. doi: 10.1016/j.prro.2014.05.002. Epub 2014 Jun 14.

PMID:
25413417
11.

Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis.

Boyle JM, Tandberg DJ, Chino JP, D'Amico TA, Ready NE, Kelsey CR.

Cancer. 2015 Feb 15;121(4):598-604. doi: 10.1002/cncr.29095. Epub 2014 Oct 3.

12.

Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.

Denehy L, Hornsby WE, Herndon JE 2nd, Thomas S, Ready NE, Granger CL, Valera L, Kenjale AA, Eves ND, Jones LW.

J Thorac Oncol. 2013 Dec;8(12):1545-50. doi: 10.1097/JTO.0000000000000032.

13.

Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?

Tandberg DJ, Gee NG, Chino JP, D'Amico TA, Ready NE, Coleman RE, Kelsey CR.

J Thorac Cardiovasc Surg. 2013 Oct;146(4):796-801. doi: 10.1016/j.jtcvs.2013.05.027. Epub 2013 Jul 16.

14.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators.

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.

15.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.

Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI.

Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26.

16.

Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.

Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD, Clough R, MacFall JR, Hoang J, Scher RL, Esclamado RM, Dunphy FR, Ready NE, Brizel DM.

Clin Cancer Res. 2012 Mar 1;18(5):1404-14. doi: 10.1158/1078-0432.CCR-11-1982. Epub 2012 Jan 17.

17.

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE.

J Clin Oncol. 2011 Nov 20;29(33):4436-41. doi: 10.1200/JCO.2011.35.6923. Epub 2011 Oct 3.

18.

Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.

Ahmed S, Birnbaum AE, Safran HP, Dipetrillo TA, Aswad BI, Ready NE, Ng T.

J Thorac Oncol. 2011 Aug;6(8):1432-4. doi: 10.1097/JTO.0b013e3182209043.

19.

How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems.

Pepek JM, Chino JP, Marks LB, D'amico TA, Yoo DS, Onaitis MW, Ready NE, Hubbs JL, Boyd J, Kelsey CR.

J Thorac Oncol. 2011 Apr;6(4):757-61. doi: 10.1097/JTO.0b013e31821038c0.

20.

Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.

Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J, Kennedy T.

Am J Clin Oncol. 2012 Feb;35(1):6-12. doi: 10.1097/COC.0b013e3182019ee3.

PMID:
21293244
Items per page

Supplemental Content

Loading ...
Write to the Help Desk